Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Development | February 13, 2026 | February 18, 2026 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Head of Research & Development | April 02, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 10,560 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 10,560 · Balance 10,560 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Larimar Therapeutics, Inc.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2029-03-03 | Direct | 375,000 |
Reported balance
After 2019-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-02 · Grant · Acquired 375,000 · Balance 375,000 F1: 25% of this option vests on March 4, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vests on March 4, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 01:17 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,560 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000034 · form4.xml · derivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,560 Underlying: Common Stock · 10,560 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 2,660 | $199.83 | $531,547.80 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · nonDerivative · entry 5 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,043.1428 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,683 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · derivative · entry 7 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 4,683 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,217 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · derivative · entry 6 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,217 Underlying: Common Stock · 2,217 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,412 | $201.18 | $284,066.16 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · nonDerivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,703.1428 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,683 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,115.1428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,056 | $201.18 | $212,446.08 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,432.1428 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:05 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000023 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,488.1428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 22:17 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 748 | $179.30 | $134,116.40 |
DisclosureSEC source: 0000875045-26-000007 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,271.1428 Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 22:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,829 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000007 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,829 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 22:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 582 | $179.89 | $104,695.98 |
DisclosureSEC source: 0000875045-26-000007 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,019.1428 Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 22:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,829 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000007 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,601.1428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 2, 2025 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 517 | $133.55 | $69,045.35 |
DisclosureSEC source: 0001127602-25-021083 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,772.1428 Read SEC document |
| August 29, 2025 Filed Sep 2, 2025 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,669 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-021083 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,669 shares Expires 2025-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| August 29, 2025 Filed Sep 2, 2025 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 807 | $132.22 | $106,701.54 |
DisclosureSEC source: 0001127602-25-021083 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,289.1428 Read SEC document |
| August 29, 2025 Filed Sep 2, 2025 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-021083 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,096.1428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:05 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 3,806 | $126.25 | $480,507.50 |
DisclosureSEC source: 0001127602-25-015011 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,427.1428 F1 · balance_after: Includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2025. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004462 · form4.xml · derivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,212 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 357 | $142.54 | $50,886.78 |
DisclosureSEC source: 0001127602-25-004462 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,066.4761 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004462 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,423.4761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:45 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003956 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,434 Underlying: Common Stock · 2,216 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:45 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 681 | $141.35 | $96,259.35 |
DisclosureSEC source: 0001127602-25-003956 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,211.4761 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:45 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003956 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,892.4761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:45 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 14,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003956 · form4.xml · derivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,050 Underlying: Common Stock · 14,050 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,828 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002817 · form4.xml · derivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,829 Underlying: Common Stock · 1,828 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 578 | $143.93 | $83,191.54 |
DisclosureSEC source: 0001127602-25-002817 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,676.4761 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002817 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,254.4761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2024 Filed Dec 9, 2024 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 110 | $157.21 | $17,293.10 |
DisclosureSEC source: 0001127602-24-028861 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,426.4761 Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028861 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 426 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on December 8, 2021 and will vest in three equal installments on each anniversary of the grant date. F2 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 206 | $157.78 | $32,502.68 |
DisclosureSEC source: 0001127602-24-028861 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,536.4761 Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028861 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,742.4761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 10:00 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 431 | $204.22 | $88,018.82 |
DisclosureSEC source: 0001127602-24-023505 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,316.4761 Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 10:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023505 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,668 shares Expires 2025-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 10:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 807 | $204.76 | $165,241.32 |
DisclosureSEC source: 0001127602-24-023505 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,747.4761 Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 10:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023505 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,554.4761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:24 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 93 | $213.09 | $19,817.37 |
DisclosureSEC source: 0001127602-24-012414 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,886.4761 F1 · balance_after: 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:54 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 262 | $221.23 | $57,962.26 |
DisclosureSEC source: 0001127602-24-006947 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,886.0915 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · derivative · entry 8 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 485 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 389 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · derivative · entry 7 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 485 Underlying: Common Stock · 389 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · derivative · entry 6 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 819 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 108 | $221.49 | $23,920.92 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · nonDerivative · entry 5 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,148.0915 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 173 | $219.08 | $37,900.84 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · nonDerivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,256.0915 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,429.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 295 | $219.08 | $64,628.60 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,040.0915 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006212 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,335.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 23:06 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 419 | $239.45 | $100,329.55 |
DisclosureSEC source: 0001127602-24-004801 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,516.0915 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004801 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,212 Underlying: Common Stock · 1,212 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 374 | $240.98 | $90,126.52 |
DisclosureSEC source: 0001127602-24-004801 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,935.0915 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004801 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,309.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 00:59 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004303 · form4.xml · derivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,650 Underlying: Common Stock · 6,650 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.